Cytotoxin derivative D-MMAE as well as preparation method and application thereof
By optimizing the chemical structure of the intermediate part of monomethyloritatin E, the new cytotoxin derivative D-MMAE was synthesized, which solved the problem of insufficient research on the diversity of intermediate parts in the existing technology, and achieved efficient synthesis and diversity , provides new ADC drug selection, enhancing the clinical application potential of drugs.
Patent Information
- Application Number
- CN202411179599.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art studies on the diversity of intermediate sites of Haitu Toxin 10 derivatives, especially monomethyloritatin E (MMAE), limiting the diversity and drug research of antibody drug conjugates (ADCs). development.
By designing a new chemical structure, the specific steps include methylation, reduction, acylation, hydrogenation, acylation, hydrolysis and deprotection reaction of compound D-1, synthesis is carried out under optimized conditions to obtain the cytotoxin derivative D-MMAE , improves its hydrophilicity and compound diversity.
The efficient synthesis and diversity of D-MMAE is achieved, and new ADC drug selection is provided, which enhances drug delivery and absorption in vivo, has potential clinical application value, and simplifies the commercial production process.
Smart Images

Figure CN119080870A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical chemical synthesis, and relates to a cytotoxin (heterotoxin) derivative for antibody-drug conjugation, and in particular to a monomethyl auristatin E derivative, a preparation method and an application thereof. Background Art
[0002] Dolastatin 10 is a linear peptide compound with anti-tumor activity extracted and isolated from the Indian Ocean sea hare. It has significant anti-cancer activity and a unique chemical structure. Dolastatin 10 is a microtubule inhibitor, and its mechanism of action is: it binds to tubulin, destroys the cytoskeleton structure of tumor cells and interferes with mitosis to kill tumor cells.
[0003] Monomethyl auristatin E (MMAE) is a synthetic derivative of Dolastatin 10. In addition to MMAE, the synthetic derivative of Dolastatin 10 also includes monomethyl auristatin F (MMAF), and the specific chemical structure is as follows:
[0004]
[0005] Both of the above are widely used as the payload component (i.e., ADC toxin) of antibody drug conjugate (ADC). Antibody drug conjugate ADC is a new type of anti-tumor drug that combines the targeting ability of antibodies and the anti-cancer ability of cytotoxins. The principle is to connect cytotoxins to antibodies, and through the recognition of specific antigens on the surface of cancer cells by antibodies, enter cancer cells through endocytosis, and thus deliver cytotoxins to the target site, achieving the purpose of targeted treatment of malignant tumors. Compared with traditional small molecule chemical drugs for treating tumors, ADC has the characteristics of precise targeting, reduces the off-target toxicity of small molecule drugs, and has better clinical safety. Structurally, ADC includes three different components: antibodies, linkers, and cytotoxins. Antibodies have high specificity and high affinity, and are responsible for guiding ADC to cancer cells. One end of the linker is connected to the antibody, and the other end is connected to the cytotoxin. The linker must remain relatively stable during blood transport, and after reaching the tumor cells, it can release cytotoxins to play a killing effect on cancer cells. Cytotoxins can be divided into microtubule inhibitors, DNA damaging agents, and RNA polymerase inhibitors according to their different mechanisms of action in clinical practice.
[0006] At present, among the 15 ADC drugs that have been applied for listing worldwide, 5 have selected MMAE and 1 has selected MMAF as the toxin part, accounting for a total of 40.0%. According to relevant reports, among the ADC drugs in the clinical stage, the proportion of clinical ADC research projects that choose MMAE as a toxin is also at the forefront. It can be seen that MMAE has been widely used in ADC drugs and research. The results of the diversity study of MMAE show that its structural modification is mainly concentrated in the N-terminus (such as the Chinese invention patent with application number CN105143199A), and there is less research on the diversity of the middle part. Therefore, it is also of great significance to carry out diversity modification of its middle part. Summary of the invention
[0007] In view of this, the purpose of the present invention is to overcome the deficiencies of the prior art and provide a new antibody drug conjugate toxin molecule D-MMAE (i.e., cytotoxin derivative D-MMAE), which can be used as a cytotoxin molecule for the preparation of ADC drugs.
[0008] In order to achieve the above object, the technical solution adopted by the present invention is: a cytotoxin derivative D-MMAE, whose chemical structure is as follows:
[0009]
[0010] Another object of the present invention is to provide a method for preparing the above-mentioned cytotoxic derivative D-MMAE, comprising the following steps:
[0011] (a) subjecting compound D-1 to a methylation reaction to obtain compound D-2; the structural formula of the compound D-1 is The structural formula of the compound D-2 is
[0012] (b) subjecting compound D-2 to a reduction reaction and salt formation to obtain compound D-3; the structural formula of the compound D-3 is
[0013] (c) subjecting compound D-3 and compound D-4 to an acylation reaction to obtain compound D-5; the structural formula of the compound D-4 is The structural formula of the compound D-5 is
[0014] (d) subjecting compound D-5 to a hydrogenation reaction to obtain compound D-6; the structural formula of the compound D-6 is
[0015] (e) subjecting compound D-6 to an acylation reaction with compound D-7 to obtain compound D-8; the structural formula of the compound D-7 is The structural formula of the compound D-8 is
[0016] (f) subjecting compound D-8 to a hydrolysis reaction to obtain compound D-9; the structural formula of the compound D-9 is
[0017] (g) subjecting compound D-9 and compound D-10 to an acylation reaction to obtain compound D-11; the structural formula of the compound D-10 is The structural formula of the compound D-11 is
[0018] (h) Deprotecting compound D-11 to obtain the cytotoxic derivative D-MMAE.
[0019] Optimally, step (a) is to dissolve compound D-1 in THF, cool to -55 to -45°C, add hexamethylphosphoric acid triamide and stir, then dropwise add bis(trimethylsilyl)amide lithium tetrahydrofuran solution, and monitor the liquid phase until the reaction is complete; quench with saturated ammonium chloride, separate the liquids, dry and concentrate, and purify with a normal phase column to obtain compound D-2.
[0020] Optimally, step (b) is to mix concentrated hydrochloric acid and ethanol at room temperature, add compound D-2 and Pd / C catalyst, react for 16 to 48 hours at room temperature and normal pressure in a hydrogen atmosphere, and monitor the completion of the reaction by HPLC; filter with diatomaceous earth on a sand core funnel, rinse the filter cake with ethanol, and concentrate the filtrate to obtain compound D-3.
[0021] Optimally, step (c) is to dissolve compound D-3 in dichloromethane in a nitrogen atmosphere, then add compound D-4 and HATU, stir at room temperature, cool to ≤10°C, add DIPEA dropwise, and react at room temperature for 16 to 24 hours; the reaction solution is quenched, washed, dried, filtered, and concentrated to obtain a crude product, which is purified by a normal phase column to obtain compound D-5.
[0022] Optimally, step (d) is to add methanol, compound D-5 and Pd(OH)2 / C to a reaction bottle, react at room temperature under normal pressure for 16 to 24 hours in a hydrogen atmosphere, and monitor the completion of the reaction of compound D-5 by HPLC; add diatomaceous earth to a sand core funnel, filter with suction, wash the filter cake with methanol, collect the filtrate, concentrate and dry to obtain compound D-6.
[0023] Optimally, step (e) is to dissolve compound D-6 in DCM at room temperature and stir, add compound D-7 and HATU in sequence and stir, add DIPEA dropwise at a temperature of ≤10°C, and after the addition is complete, warm to room temperature to react for 3 to 4 hours, and HPLC detects that the reaction is complete; quench, separate, dry and concentrate to obtain a crude product, stir and separate with a mixed solvent of methanol and dilute hydrochloric acid, concentrate and spin-dry to obtain compound D-8.
[0024] Optimally, step (f) is to add compound D-8 and DCM to a reaction bottle at room temperature, cool in an ice-water bath and stir, and add TFA dropwise at ≤10°C, warm to room temperature and react for 16 to 24 hours, and detect the completion of the reaction by HPLC; wash the reaction solution with water and saturated brine, and dry and concentrate the organic phase to obtain a pale yellow foam crude product; the crude product is crystallized with a mixed solvent of ethyl acetate and petroleum ether to obtain compound D-9.
[0025] Optimally, step (g) is to add dichloromethane and compound D-10 to a reaction vessel under nitrogen protection at room temperature, and then add compound D-9 and HATU in sequence under stirring. After stirring at room temperature, cool to ≤10°C, add DIPEA dropwise and warm to room temperature to react for 4-6 hours. HPLC detection shows that the reaction is complete; the reaction solution is washed, separated, dried and concentrated to obtain compound D-11.
[0026] Optimally, step (h) is to add acetonitrile to compound D--11 in a reaction vessel, add diisopropylamine DIPA at ≤10°C, warm to room temperature and react for 25-35h, detect the reaction is complete by HPLC, concentrate to obtain a crude product, and purify it by normal phase column.
[0027] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art: the cytotoxin derivative D-MMAE of the present invention has a novel chemical structure (one of the methoxy groups is demethylated to a hydroxyl group on the L-isoleucine fragment), which has better hydrophilicity and forms a new compound, which plays an optimized regulatory role in the delivery and absorption of drugs in the body and has the potential to become a drug. As a commonly used "warhead" molecule in ADC drugs, the derivatives provided by the present invention can provide ADC drugs with a variety of cytotoxins and provide more options for drug research and development.
[0028] The preparation method of the cytotoxin derivative D-MMAE of the present invention realizes the efficient synthesis of D-MMAE, is easy to scale up, and is convenient for commercial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The figure is a process flow chart of the preparation of the cytotoxin derivative D-MMAE of the present invention;
[0030] Figure 2 HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-2) of the present invention;
[0031] Figure 3 LC-MS spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-2) of the present invention;
[0032] Figure 4The intermediate of the cytotoxin derivative D-MMAE (compound D-2) of the present invention 1 H-NMR spectrum;
[0033] Figure 5 HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-3) of the present invention;
[0034] Figure 6 The intermediate of the cytotoxin derivative D-MMAE (compound D-3) of the present invention 1 H-NMR spectrum;
[0035] Figure 7 LC-MS spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-5) of the present invention;
[0036] Figure 8 HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-5) of the present invention;
[0037] Fig. 9 LC-MS spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-6) of the present invention;
[0038] Fig.10 HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-6) of the present invention;
[0039] Fig.11 LC-MS spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-8) of the present invention;
[0040] Fig.12 HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-8) of the present invention;
[0041] Fig.13 LC-MS spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-9) of the present invention;
[0042] Fig.14 HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-9) of the present invention;
[0043] Fig.15 The intermediate of the cytotoxin derivative D-MMAE (compound D-9) of the present invention 1 H-NMR spectrum;
[0044] Fig.16 LC-MS spectrum of the cytotoxin derivative D-MMAE intermediate (Compound D-11) of the present invention;
[0045] Fig.17 is the HPLC spectrum of the cytotoxic derivative D-MMAE of the present invention;
[0046] Fig.18 is the LC-MS spectrum of the cytotoxin derivative D-MMAE of the present invention;
[0047] Fig.19 The cytotoxic derivative D-MMAE of the present invention 1 H-NMR spectrum;
[0048] Fig. 20 HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-21) of the present invention;
[0049] Fig.21 It is the HPLC spectrum of the cytotoxin derivative D-MMAE intermediate (compound D-2) of the present invention. DETAILED DESCRIPTION
[0050] The preferred embodiments of the present invention will be described in detail below.
[0051] Example 1
[0052] This example provides a method for preparing a cytotoxin derivative D-MMAE intermediate (compound D-2), such as Figure 1 As shown, the details are as follows:
[0053]
[0054] At room temperature 20-25°C and under nitrogen protection, compound D-1 (50 g, 1.0 eq, 136.8 mmol) and 600 ml of anhydrous THF were added to a three-necked reaction flask. After stirring to dissolve, the temperature was lowered to -55°C (or below), and hexamethylphosphoric acid triamide (HMPA, 73.6 g, 3.0 eq) was added dropwise. After the addition was complete, the reaction was kept warm for 0.5 hour. After the addition was complete, lithium bis(trimethylsilyl)amide tetrahydrofuran solution (LiHMDS, 1 mol / L, 150 ml, 1.1 eq) was added dropwise, and the reaction was kept warm for 0.5 hour. The temperature was controlled at -50°C (or below) and methyl trifluoromethanesulfonate (MeOTf, 22.45 g, 1.0 eq) was added dropwise. The reaction was kept warm for 1 to 1.5 hours. The reaction conversion was greater than 50% under HPLC monitoring. Post-treatment: the reaction solution was quenched with 60 ml of saturated ammonium chloride, extracted twice with 500 ml of ethyl acetate, the organic phases were combined, washed four times with saturated ammonium chloride (300 ml each time), washed once with 300 ml of saturated sodium chloride, dried over 100 g of anhydrous sodium sulfate, concentrated and spin-dried to obtain 53 g of crude compound D-2.
[0055] The crude product was purified by normal phase column with ethyl acetate petroleum ether (PE: EA = 50: 1) to obtain 18.5 g of pure compound D-2 (such as Figures 2 to 4 HPLC purity 97.9%, LCMS: 380.44 [M+H] + . NMR data 1 H-NMR (400MHz, CDCl3) δ7.37-7.33 (m, 4H), 7.31 (dd, J=9.0, 4.7Hz, 1H), 5.11 (t, J=15.6Hz, 2H), 4.67 (d, J=9.4Hz, 1H), 3.72 (p, J= 6.9Hz, 2H), 3.37 (s, 3H), 2.40 (d, J=5.4Hz, 2H), 1.64-1.53 (m, 2H), 1.44 (s, 9H), 1.08-0.98 (m, 1H), 0.91 (dd, J=14.2, 7.0Hz, 6H).
[0056] This embodiment also provides a method for preparing a cytotoxin derivative D-MMAE intermediate (compound D-3), such as Figure 1 As shown, the details are as follows:
[0057]
[0058] At room temperature 20-25°C, 2.8 ml (1.1 eq) of concentrated hydrochloric acid and 60 ml of ethanol were mixed and stirred evenly, and compound D-212 g (1.0 eq, 30.5 mmol) was added. 2.4 g of 10% Pd / C was added under stirring, and hydrogen was replaced 2-3 times. The reaction was carried out at room temperature under normal pressure for 16-48 hours, and the reaction was completed by HPLC monitoring. Post-treatment: Filter with diatomaceous earth pad on a sand core funnel, rinse the filter cake with an appropriate amount of ethanol, concentrate the combined filtrate, and dry it in a vacuum to obtain 8.8 g of compound D-3 (such as Figures 5 and 6 As shown), yield 87.5%. HPLC 99.8%, NMR data: 1 H NMR (400MHz, DMSO) δ8.09 (s, 3H), 3.83 (dt, J=9.9, 3.0Hz, 1H), 3.44 (q, J=7.0Hz, 1H), 3.15 (s, 1H), 2.54-2.48 (m, 1H), 2.33 (dd , J=15.8, 10.1Hz, 1H), 1.69-1.57 (m, 2H), 1.42 (s, 9H), 1.17-1.10 (m, 1H), 1.05 (d, J=7.0Hz, 1H), 0.87 (dd, J=15.0, 7.1Hz, 6H).
[0059] This embodiment also provides a method for preparing a cytotoxin derivative D-MMAE intermediate (compound D-5), such as Figure 1 As shown, the details are as follows:
[0060]
[0061] Under nitrogen protection, 40 ml of dichloromethane and 7.8 g (24.5 mmol, 1.0 eq) of compound D-3 were added to a three-necked flask, and compound D-4 (Z-Val-OH, 6.6 g, 0.95 eq) and HATU (12.6 g, 1.20 eq) were added in sequence under stirring. After stirring at room temperature for 30 min, DIPEA (14.3 g, 4.0 eq) was added dropwise while controlling the temperature below 10 °C. After the addition was completed, the temperature was naturally raised to room temperature and the reaction was carried out for 16 to 24 h. The reaction was complete when detected by HPLC.
[0062] Post-treatment: The reaction system was washed with 40 ml of 10% citric acid aqueous solution (mass concentration, the same below), 40 ml of saturated sodium bicarbonate solution, and 40 ml of saturated brine. The organic layer was dried over 20 g of anhydrous sodium sulfate, filtered, and concentrated to obtain 26 g of crude compound D-5.
[0063] The crude compound D-5 was dissolved in 26 ml of methanol, and 30 ml (1 mol / L) of dilute hydrochloric acid was added dropwise under stirring at 0-5 °C. The mixture was stirred at room temperature for 2 h, and then the stirring was stopped. The filter cake was filtered with suction, and washed with an appropriate amount of methanol. The filter cake was dried under vacuum to obtain 12.5 g of compound D-5. The crude product yield was 106.5% (the product contained salt and other impurities, such as Figures 7 and 8 HPLC purity 88.9% (actual yield is 88.9%×106.5%=94.7%), LCMS: 479.50[M+H] + .
[0064] This embodiment also provides a method for preparing a cytotoxin derivative D-MMAE intermediate (compound D-6), such as Figure 1 As shown, the details are as follows:
[0065]
[0066] In a three-necked flask, add 30 ml of methanol, 12 g of compound D-5 and 3.6 g of 10% Pd(OH)2 / C, replace the gas with hydrogen three times, react at room temperature under normal pressure for 16 to 24 hours, and monitor the complete reaction of the raw materials with HPLC. Post-treatment: Add diatomaceous earth to the sand core funnel, filter with suction, wash the filter cake with 30 ml of methanol, collect the filtrate, evaporate the filtrate to dryness, and vacuum dry to obtain 7.5 g of compound D-6 with a yield of 87.2% (such as Figures 9 and 10 HPLC purity 89.3%, LCMS: 345.50 [M+H] + .
[0067] This embodiment also provides a method for preparing a cytotoxin derivative D-MMAE intermediate (compound D-8), such as Figure 1 As shown, the details are as follows:
[0068]
[0069] At room temperature 20-25°C, compound D-6 (7.5 g, 21.8 mmol, 1.0 eq) was dissolved in 50 ml of DCM and stirred thoroughly. Compound D-7 (Fmoc-Me-val, 7.7 g 1.0 eq) and HATU (9.9 g, 1.2 eq) were added in sequence. After stirring at room temperature for 30 min, DIPEA (5.8 g, 2.0 eq) was added dropwise at a temperature below 0°C. After the addition was completed, the temperature was naturally raised to room temperature and the reaction was carried out for 3-4 h. The reaction was complete when detected by HPLC.
[0070] Post-treatment: Add 40 ml of water to the reaction solution for washing and separation, then wash with 40 ml of 10% citric acid aqueous solution, 40 ml of saturated sodium bicarbonate solution, and 40 ml of saturated brine. Dry the organic layer with 15 g of anhydrous sodium sulfate, filter it, concentrate and spin-dry to obtain 22 g of a crude product.
[0071] The crude product was dissolved in 22 ml of methanol, and 11 ml (1 mol / L) of dilute hydrochloric acid was added dropwise under stirring in an ice-water bath. The mixture was stirred at room temperature for 1.5-2 h, and the stirring was stopped. The upper aqueous layer was separated and the operation was repeated once. The organic phase was concentrated, dried under vacuum, and 14.0 g of compound D-8 was obtained. The yield was 94.5% (as Figure 11 to Figure 12 HPLC purity 93.2%, LCMS: 680.72 [M+H] + .
[0072] This embodiment also provides a method for preparing a cytotoxin derivative D-MMAE intermediate (compound D-9), such as Figure 1 As shown, the details are as follows:
[0073]
[0074] At room temperature 20-25°C, add compound D-8 (14 g, 20.9 mmol, 1.0 eq) and 42 ml DCM into a three-necked flask, stir to dissolve completely, cool to below 10°C, add 21 ml TFA dropwise, and naturally raise the temperature to room temperature 20-25°C after addition. React for 16-24 hours. HPLC detection shows that the raw material reaction is complete.
[0075] Post-treatment: The reaction solution was washed with water 4 times (40 ml each time) and saturated brine once (40 ml). The organic phase was dried over 15 g Na2SO4, filtered and concentrated to obtain 13 g of pale yellow foam crude compound D-9;
[0076] Purification: 13 g crude compound D-9 was added to EA (13 ml) to dissolve completely, and 52 ml PE was added dropwise under stirring. The suspension was stirred for 1 hour and then filtered. The filter cake was washed with a small amount of mixed solvent (PE: EA = 4:1) and vacuum dried to obtain the qualified product compound D-9, 8.5 g, with a yield of 66.4% (such as Figures 13 to 15 HPLC purity 97.1%, LC-MS: 624.60 [M+H] + , NMR data: 1 H NMR (400MHz, DMSO) δ12.14 (s, 1H), 7.90 (d, J = 7.4Hz, 2H), 7.70 (d, J = 9.0Hz, 2H), 7.62 (d, J = 7.4Hz, 1H), 7.43 (dd, J = 16.4, 8 .9Hz, 3H), 7.32 (dd, J=7.4, 6.7Hz, 2H), 4.47-4.27 (m, 3H), 4.21 (d, J=11.0Hz, 1H), 4.13-4.07 (m, 1H), 3.96-3.90 (m, 1H), 3 .69 (s, 1H), 3.22 (d, J = 9.8Hz, 3H), 2.78 (d, J = 22.6Hz, 3H), 2.35 (d, J = 14.5Hz, 1H), 2.16 (dd, J = 15.9, 9.9Hz, 1H), 2.10-2.0 2 (m, 1H), 1.89 (dd, J=13.8, 6.9Hz, 1H), 1.50-1.39 (m, 2H), 1.24 (s, 1H), 1.07 (dd, J=14.4, 7.4Hz, 1H), 0.88-0.71 (m, 20H).
[0077] This embodiment also provides a method for preparing a cytotoxin derivative D-MMAE intermediate (compound D-11), such as Figure 1 As shown, the details are as follows:
[0078]
[0079] Under nitrogen protection, 45 mL of dichloromethane and compound D-10 (3.0 g, 8.4 mmol, 1.0 eq) were added to a three-necked flask at room temperature of 20-25 ° C. D-9 (4.98 g, 0.95 eq) and HATU (3.84 g, 1.20 eq) were added in sequence under stirring. After stirring at room temperature for 30 min, the temperature was lowered and DIPEA (3.27 g, 3.0 eq) was added dropwise at a temperature below 10 degrees. After the addition was completed, the temperature was naturally raised to room temperature for 4-6 hours. The reaction was complete when HPLC was detected.
[0080] Post-treatment: The reaction solution was washed with 10% citric acid aqueous solution (90 mL), saturated sodium bicarbonate solution (90 mL), and saturated brine (90 mL) in sequence. The organic phase was dried over anhydrous sodium sulfate and concentrated by rotary evaporation to obtain 7.5 g of compound D-11 with a yield of 96.4% (such as Fig.16 LCMS: 926.68.
[0081] This embodiment also provides a method for preparing a cytotoxic derivative D-MMAE, such as Figure 1 As shown, the details are as follows:
[0082]
[0083] At room temperature 20-25°C, under nitrogen protection, in a 100mL three-necked flask, add 17.5g of the crude compound D-1 from the previous step to 38ml of acetonitrile and stir thoroughly, add diisopropylamine (DIPA 19ml, 2.5 times volume) at 10°C, naturally warm to room temperature, and react for 24-36h. HPLC detection of the reaction is complete.
[0084] After treatment, the reaction solution was directly concentrated, dissolved with 15 ml of DCM, and then evaporated 2 to 3 times to obtain a crude compound D-MMAE;
[0085] Normal phase column purification: the crude product was mixed with 15g of 100-200 mesh silica gel DCM 30ml to make sand, 120g loading capacity pre-loaded column, 220nm wavelength detection, 100ml / min, dry loading. Purification was performed with a dichloromethane-methanol mixed system, dichloromethane / methanol = 25 / 1 to obtain a qualified eluent, which was concentrated and dried to obtain 2.5g of an off-white solid compound D-MMAE (i.e., a cytotoxic derivative D-MMAE), with a two-step yield of 42.4% (e.g. Figures 17 to 19 HPLC purity 96.9%, LCMS: 704.85 [M+H] + , NMR data: 1H NMR (400MHz, DMSO) δ7.91 (t, J=7.8Hz, 1H), 7.70 (d, J=9.9Hz, 1H), 7.63 (d, J=8.5Hz, 1H), 7.33-7.24 (m, 4H), 7.21-7.15 (m , 1H), 5.36 (dd, J=17.7, 4.8Hz, 1H), 4.50 (t, J=5.3Hz, 1H), 4.30-4.19 (m, 1H), 3.96 (ddd, J=18.6, 12.4, 6.3Hz, 2H), 3.78 (d d, J=17.0, 7.5Hz, 2H), 3.64 (d, J=6.0Hz, 1H), 3.45 (t, J=10.9Hz, 1H), 3.16 (s, 3H), 2.73 (d, J=6.1Hz, 5H), 2.19 (d, J=7.0H z, 4H), 1.80 (dtd, J=33.5, 13.5, 6.5Hz, 4H), 1.62-1.49 (m, 2H), 1.47-1.38 (m, 2H), 1.07-0.96 (m, 9H), 0.92-0.75 (m, 20H).
[0086] At room temperature of 20-25°C, solubility test data showed that 1g D-MMAE can be completely dissolved in 5ml water + 1ml acetonitrile, while 1g MMAE requires 5ml water + 5ml acetonitrile to be completely dissolved. In comparison, D-MMAE has better water solubility and hydrophilicity.
[0087] Comparative Example 1
[0088] This example provides a method for preparing a cytotoxin derivative D-MMAE intermediate, which is as follows:
[0089]
[0090] At room temperature of 20-25°C and under nitrogen protection, compound D-1 (50 g, 1.0 eq, 136.8 mmol) and 600 ml of anhydrous THF were added to a three-necked reaction flask. After stirring until dissolved, the temperature was lowered to -55°C (or below), and hexamethylphosphoric triamide (HMPA, 73.6 g, 3.0 eq) was added dropwise. After the addition was complete, the mixture was kept warm for 0.5 hour. After the addition was complete, lithium bis(trimethylsilyl)amide tetrahydrofuran solution (LiHMDS, 1 mol / L, 273.7 ml, 2.0 eq) was added dropwise. The mixture was kept warm for 0.5 hour. Methyl trifluoromethanesulfonate (MeOTf, 22.45 g, 1.0 eq) was added dropwise at -50 °C (or below) and the reaction was kept warm for 1 to 1.5 hours. The conversion rate of D-2 was 8.2% under HPLC monitoring, and most of it was converted to D-21 with a conversion rate of 49.1%. The conversion rate of D-2 did not increase with the extension of the reaction time, but the conversion rate of D22 increased. Due to the low conversion rate, no further separation and purification was performed (such as Fig. 20 shown);
[0091] After the reaction conditions were optimized (see Example 1), compound D-1 (50 g, 1.0 eq, 136.8 mmol) and anhydrous THF 600 ml were added to a three-necked reaction bottle at room temperature of 20 to 25 ° C. and under nitrogen protection. After stirring and dissolving, the temperature was lowered to -55 ° C (or below), and hexamethylphosphoryl triamide (HMPA, 73.6 g, 3.0 eq) was added dropwise. After the addition was completed, the reaction was kept warm for 0.5 hours. Lithium bis(trimethylsilyl)amide tetrahydrofuran solution (LiHMDS, 1 mol / L, 150 ml, 1.1 eq) was added dropwise. The reaction was kept warm for 0.5 hours. Methyl trifluoromethanesulfonate (MeOTf, 22.45 g, 1.0 eq) was added dropwise at -50 ° C (or below), and the reaction was kept warm for 1.2 hours. The conversion rate of D-2 was monitored to reach 52.2% (such as Fig.21 After post-treatment with a normal phase column, 18.5 g of pure compound D-2 was obtained with a yield of 35.6%.
[0092] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.
Claims
1. A cytotoxin derivative D-MMAE, characterized in that Its chemical structure is:
2. The method for preparing the cytotoxic derivative D-MMAE according to claim 1, characterized in that: The following steps are involved: (a) subjecting compound D-1 to a methylation reaction to obtain compound D-2; the structural formula of the compound D-1 is The structural formula of the compound D-2 is (b) subjecting compound D-2 to a reduction reaction and salt formation to obtain compound D-3; the structural formula of the compound D-3 is (c) subjecting compound D-3 and compound D-4 to an acylation reaction to obtain compound D-5; the structural formula of the compound D-4 is The structural formula of the compound D-5 is (d) subjecting compound D-5 to a hydrogenation reaction to obtain compound D-6; the structural formula of the compound D-6 is (e) subjecting compound D-6 to an acylation reaction with compound D-7 to obtain compound D-8; the structural formula of the compound D-7 is The structural formula of the compound D-8 is (f) subjecting compound D-8 to a hydrolysis reaction to obtain compound D-9; the structural formula of the compound D-9 is (g) subjecting compound D-9 and compound D-10 to an acylation reaction to obtain compound D-11; the structural formula of the compound D-10 is The structural formula of the compound D-11 is (h) Deprotecting compound D-11 to obtain the cytotoxic derivative D-MMAE.
3. The method for preparing the cytotoxic derivative D-MMAE according to claim 2, characterized in that: Step (a) is to dissolve compound D-1 in THF, cool to -55 to -45°C, add hexamethylphosphoric triamide and stir, then dropwise add lithium bis(trimethylsilyl)amide tetrahydrofuran solution, and monitor the liquid phase until the reaction is complete; quench with saturated ammonium chloride, separate the liquids, dry and concentrate, and purify with a normal phase column to obtain compound D-2.
4. The method for preparing the cytotoxic derivative D-MMAE according to claim 2, characterized in that: Step (b) is to mix concentrated hydrochloric acid and ethanol at room temperature, add compound D-2 and Pd / C catalyst, react for 16 to 48 hours at room temperature and normal pressure in a hydrogen atmosphere, and monitor the completion of the reaction by HPLC; filter with diatomaceous earth pad on a sand core funnel, rinse the filter cake with ethanol, and concentrate the filtrate to obtain compound D-3.
5. The method for preparing the cytotoxic derivative D-MMAE according to claim 2, characterized in that: Step (c) is to dissolve compound D-3 in dichloromethane in a nitrogen atmosphere, then add compound D-4 and HATU, stir at room temperature, cool to ≤10°C, add DIPEA dropwise, and react at room temperature for 16 to 24 hours; the reaction solution is quenched, washed, dried, filtered, and concentrated to obtain a crude product, which is purified by a normal phase column to obtain compound D-5.
6. The method for preparing the cytotoxin derivative D-MMAE according to claim 2, characterized in that: Step (d) is to add methanol, compound D-5 and Pd(OH)2 / C to a reaction bottle, react at room temperature under normal pressure for 16 to 24 hours in a hydrogen atmosphere, and monitor the completion of the reaction of compound D-5 by HPLC; add diatomaceous earth to a sand core funnel, filter with suction, wash the filter cake with methanol, collect the filtrate, concentrate and dry to obtain compound D-6.
7. The method for preparing the cytotoxic derivative D-MMAE according to claim 2, characterized in that: Step (e) is to dissolve compound D-6 in DCM at room temperature and stir, add compound D-7 and HATU in sequence and stir, add DIPEA dropwise at a temperature of ≤10°C, and after the addition is complete, warm to room temperature to react for 3 to 4 hours. HPLC detects that the reaction is complete; quench, separate, dry and concentrate to obtain a crude product, stir and separate with a mixed solvent of methanol and dilute hydrochloric acid, concentrate and spin-dry to obtain compound D-8.
8. The method for preparing the cytotoxin derivative D-MMAE according to claim 2, characterized in that: Step (f) is to add compound D-8 and DCM to a reaction bottle at room temperature, cool in an ice-water bath, stir, and dropwise add TFA at ≤10°C, warm to room temperature and react for 16 to 24 hours, and detect the completion of the reaction by HPLC; wash the reaction solution with water and saturated brine, and dry and concentrate the organic phase to obtain a pale yellow foam crude product; the crude product is crystallized with a mixed solvent of ethyl acetate and petroleum ether to obtain compound D-9.
9. The method for preparing the cytotoxic derivative D-MMAE according to claim 2, characterized in that: Step (g) is to add dichloromethane and compound D-10 to a reaction vessel under nitrogen protection at room temperature, and then add compound D-9 and HATU in sequence under stirring. After stirring at room temperature, cool to ≤10°C, add DIPEA dropwise and warm to room temperature to react for 4-6 hours. HPLC detection shows that the reaction is complete; the reaction solution is washed, separated, dried and concentrated to obtain compound D-11.
10. The method for preparing the cytotoxin derivative D-MMAE according to claim 2, characterized in that: Step (h) is to add acetonitrile to compound D-11 in a reaction container, add diisopropylamine DIPA at ≤10°C, warm to room temperature and react for 25-35h, detect the reaction completion by HPLC, concentrate to obtain a crude product, and purify by normal phase column.
